Ameritas Investment Partners’s Tectonic Therapeutic TECX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$34.7K Hold
1,122
﹤0.01% 2307
2025
Q4
$23.4K Hold
1,122
﹤0.01% 2562
2025
Q3
$17.6K Hold
1,122
﹤0.01% 2720
2025
Q2
$22.3K Buy
+1,122
New +$22.7K ﹤0.01% 2609
2022
Q2
Sell
-227
Closed -$4K 3263
2022
Q1
$4K Hold
227
﹤0.01% 3014
2021
Q4
$11K Hold
227
﹤0.01% 2881
2021
Q3
$15K Hold
227
﹤0.01% 2828
2021
Q2
$24K Hold
227
﹤0.01% 2659
2021
Q1
$35K Hold
227
﹤0.01% 2292
2020
Q4
$38K Hold
227
﹤0.01% 2149
2020
Q3
$36K Hold
227
﹤0.01% 2044
2020
Q2
$48K Buy
227
+84
+59% +$17.3K ﹤0.01% 1860
2020
Q1
$27K Hold
143
﹤0.01% 2015
2019
Q4
$34K Hold
143
﹤0.01% 2133
2019
Q3
$24K Buy
143
+55
+63% +$12.5K ﹤0.01% 2298
2019
Q2
$17K Buy
88
+46
+110% +$9.92K ﹤0.01% 2544
2019
Q1
$11K Hold
42
﹤0.01% 2671
2018
Q4
$8K Hold
42
﹤0.01% 2749
2018
Q3
$26K Buy
+42
New +$18.6K ﹤0.01% 2380

Other funds holding TECX

Ameritas Investment Partners's TECX Position: Q1 2026 in Review

Ameritas Investment Partners held its Tectonic Therapeutic (TECX) position steady in Q1 2026 at 1,122 shares worth $34.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2307.

Ameritas Investment Partners first reported a position in TECX in Q3 2018 and has held it in 19 quarters since. The position peaked at $48K in Q2 2020. 111 funds tracked by Wall St. Rank hold TECX as of Q1 2026.

  • Ameritas Investment Partners held 1,122 shares of Tectonic Therapeutic worth $34.7K as of Q1 2026.
  • Ameritas Investment Partners left its Tectonic Therapeutic share count unchanged in Q1 2026.
  • Tectonic Therapeutic made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q1 2026, its #2307 holding.
  • Ameritas Investment Partners first reported a position in Tectonic Therapeutic in Q3 2018 and has held it in 19 quarters since.
  • Ameritas Investment Partners's Tectonic Therapeutic position peaked at $48K in Q2 2020.
  • 111 funds tracked by Wall St. Rank held Tectonic Therapeutic as of Q1 2026.

Based on Ameritas Investment Partners's 13F filing for Q1 2026, filed 13 May 2026.